住院医师规范化培训制度对临床医学生就业的影响

目的通过对2019年2月-2019年6月在西安交通大学第二附属医院实习的大学四年级及大学五年级的临床医学专业的医学生就业意向及就业情况的分析,研究住院医师规范化培训制度对医学生就业的影响。方法运用自制的问卷进行匿名填写的方式对大学四年级、大学五年级的临床医学本科生及5+3模式的规范化培训医学生进行调查。结果大部分医学生选择继续升学,选择就业的学生多愿意留在大城市就业,选择住院医师规范化培训的学生只占极少数。结论做好住院医师规范化培训政策的宣传,落实各项优惠政策,鼓励学生进行住院医师规范化培训及到基层工作,引导学生理性考研,是目前社会及医学院校就业指导中的重要内容。     

Proxalutamide in metastatic castration-resistant prostate cancer: Primary analysis of a multicenter,randomized, open-label,phase 2 trial

We aim to assess the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, for men with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter, randomized, open-label, phase 2 trial. In our study, the enrolled mCRPC patients were randomized to 100, 200 and 300 mg dose groups at 1:1:1. The primary efficacy endpoint was prostate-specific antigen (PSA) response rate. The secondary endpoints included objective response rate (ORR), disease control rate (DCR) and time to PSA and radiographic progression. Safety and pharmacokinetics were also assessed. Finally, there were 108 patients from 17 centers being enrolled. By week 16, there were 13 (35.1%), 12 (36.4%) and 15 (42.9%) patients with confirmed 50% or greater PSA decline in 100 mg (n = 37), 200 mg (n = 33) and 300 mg (n = 35) groups, respectively. Among the 19 patients with target lesions at study entry, three (15.8%) had a partial response and 12 (63.2%) had stable disease. The ORRs of 20.0%, 22.2%, 0% and DCRs of 80.0%, 88.9%, 60.0% were, respectively, achieved in 100, 200 and 300 mg groups. By the maximum follow-up time of 24 weeks, there were 42.6% and 10.2% of cases experiencing PSA progression and radiographic progression, respectively. Overall, adverse events (AEs) were experienced by 94.4% of patients, most of which were mild or moderate. There were 28 patients experiencing ≥grade 3 AEs. The most common AEs were fatigue (17.6%), anemia (14.8%), elevated AST (14.8%) and ALT (13.0%), decreased appetite (13.0%). These findings preliminarily showed the promising antitumor activity of proxalutamide in patients with mCRPC with a manageable safety profile. The proxalutamide dose of 200 mg daily is recommended for future phase 3 trial (Clinical trial registration no. CTR20170177).     

Searching for prognostic biomarkers for small renal masses in the urinary proteome

Renal cell carcinoma (RCC) is frequently diagnosed incidentally as an early-stage small renal mass (SRM; pT1a, ≤4 cm). Overtreatment of patients with benign or clinically indolent SRMs is increasingly common and has resulted in a recent shift in treatment recommendations. There are currently no available biomarkers that can accurately predict clinical behavior. Therefore, we set out to identify early biomarkers of RCC progression. We employed a quantitative label-free liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) proteomics approach and targeted parallel-reaction monitoring to identify and validate early, noninvasive urinary biomarkers for RCC-SRMs. In total, we evaluated 115 urine samples, including 33 renal oncocytoma (≤4 cm) cases, 30 progressive and 26 nonprogressive clear cell RCC (ccRCC)-SRM cases, in addition to 26 healthy controls. We identified six proteins, which displayed significantly elevated expression in clear cell RCC-SRMs (ccRCC-SRMs) relative to healthy controls. Proteins C12ORF49 and EHD4 showed significantly elevated expression in ccRCC-SRMs compared to renal oncocytoma (≤4 cm). Additionally, proteins EPS8L2, CHMP2A, PDCD6IP, CNDP2 and CEACAM1 displayed significantly elevated expression in progressive relative to nonprogressive ccRCC-SRMs. A two-protein signature (EPS8L2 and CCT6A) showed significant discriminatory ability (areas under the curve: 0.81, 95% CI: 0.70–0.93) in distinguishing progressive from nonprogressive ccRCC-SRMs. Patients (Stage I–IV) with EPS8L2 and CCT6A mRNA alterations showed significantly shorter overall survival (p = 1.407 × 10⁻⁶) compared to patients with no alterations. Our in-depth proteomic analysis identified novel biomarkers for early-stage RCC-SRMs. Pretreatment characterization of urinary proteins may provide insight into early RCC progression and could potentially help assign patients to appropriate management strategies.     

“从肠论治”脓毒症截断扭转防治策略的理论与实践

脓毒症是机体应对感染失控反应所致威胁生命的器官功能障碍,其病死率居高不下,全球大约每年大约有530万患者死亡,故深入探究脓毒症的发病机制和寻找有效的治疗药物是目前医学界的重要课题。中医药治疗脓毒症具有潜在优势,本团队在继承朱良春国医大师、国家非物质文化遗产“顾氏外科”奠基人顾伯华教授学术经验基础上,通过临床实践,首次提出"从肠论治”截断扭转防治脓毒症策略,为中医药治疗脓毒症提供了新的思路。     

川芎嗪通过激活PKCα/Nrf2信号转导抑制七氟烷诱导的氧化损伤和血脑屏障破坏研究

目的:研究川芎嗪对七氟烷引起的氧化损伤以及血脑屏障(BBB)生理功能损伤的影响及其机制。方法:将新生幼鼠随机分组,设置对照组,并分别使用七氟烷、七氟烷和溶剂、七氟烷和川芎嗪处理小鼠,暴露于七氟烷中不同时长处死并收集小鼠大脑和海马组织,通过免疫酶联吸附检测ROS,SOD,MDA,GSH和S100β蛋白水平,制作小鼠大脑和海马组织切片并通过免疫化学染色和免疫荧光染色检测小鼠大脑和海马组织中MMP-2、MMP-9、TIMP-1、TIMP-2以及HO-1的表达,并检测Nrf2的核易位,HE染色后通过透射电子显微镜检查海马神经元损伤情况,通过蛋白质印迹分析PKC/Nrf2以及MMP-2、MMP-9表达情况,使用原位酶谱检测明胶酶活性并通过PCR检测ZO-1的表达。结果:与对照组相比,七氟烷组海马神经元损伤明显,而川芎嗪处理可以明显改善七氟烷诱导的海马神经元损伤; 与对照组相比,七氟烷处理后MMP-2、MMP-9表达和明胶酶活性明显增加,ZO-1表达明显减少,BBB通透性显著增加,而TIMP-1和TIMP-2表达无显著改变; 与七氟烷组相比,川芎嗪可以抑制明胶酶活性,促进ZO-1表达,改善BBB生理状态; 与溶剂组和七氟烷组相比,对照组和川芎嗪组ROS和BMD水平明显降低,MDA和GSH活性显著增加,PKCα、Nrf2和HO-1 的表达以及Nrf2的核易位显著增加。结论:川芎嗪可以通过PKCα/Nrf2信号通路以及抑制明胶酶活性,改善BBB通透性,保护海马免受氧化应激的伤害,改善海马体组织病理学结构。     

Risk factors for acute kidney injury (AKI) in infants with melamine-associated urolithiasis and follow-up: a multi-center retrospective analysis

An epidemic of urinary tract stones was noted among infants in China, 2008. This event was believed to be associated with consumption melamine-contaminated powdered formula. The patients with symptoms and clinical manifests had already been analyzed in our previous studies. In this study, our aim is to investigate the risk factors of melamine-associated acute kidney injury (AKI) and the potential relationship toward children growth in our five years follow-up. A total of 619 infants with melamine-associated urolithiasis were admitted into 20 different hospitals in the Gansu province, China. All clinical data were divided into AKI and control groups according to the occurrence of AKI. Univariate and multivariate analyses were performed with a logistic regression model to assess the independent risk factors of AKI. Logistic regression analysis revealed that the odds ratio (OR) of AKI was 19.62 in the group of infants who consumed Sanlu® milk powdered infant milk formula. A higher prevalence of AKI was observed in infants age of 6–11 months (OR: 9.59, p?p?p?相似文献   

维持性血液透析病人益处发现现状及其影响因素分析

目的分析维持性血液透析（maintenance hemodialysis,MHD）病人益处发现现状并探讨其影响因素。方法采用便利抽样法选取161例MHD病人为研究对象,采用一般资料调查表、益处发现量表、生命意义感量表、家庭关怀度量表进行调查。结果不同文化程度、婚姻状况、居住地、透析龄、职业、家庭月收入和医疗费用支付方式的MHD病人益处发现得分差异均有统计学意义（P < 0.05~P < 0.01）。MHD病人益处发现总分为（38.32±6.73）分,生命意义感总分为（32.17±8.85）分,家庭关怀度总分为（6.54±2.22）分。MHD病人益处发现总分与生命意义感、存在生命意义、寻找生命意义、家庭关怀度总分均呈明显正相关关系（r=0.749、0.629、0.768、0.594,P < 0.01）。多元线性回归分析显示,文化程度、透析龄、生命意义感、家庭关怀度是维持性血液透析病人益处发现水平的影响因素（P < 0.05）。结论MHD病人益处发现处于较低水平,护士应重视疾病知识宣教,引导病人关注疾病的积极意义,并采取相应措施提高病人家庭关怀度及生命意义感,从而提高益处发现水平。     

肌肉骨骼系统慢性疼痛管理专家共识

肌肉骨骼系统慢性疼痛是临床最常见的慢性疼痛。目前,国内外医师对慢性疼痛的认识、临床实践环境、镇痛药物种类/使用经验/了解程度、医保药品收录均有差异,故有效、规范化的慢性疼痛管理显得尤为必要。因此,亟待制定完善的、基于生物-心理-社会医学等因素的跨学科慢性疼痛管理共识,提高广大医务人员对慢性疼痛的认识与重视、规范指导慢性疼痛的管理,提高医疗质量、降低医疗成本,消除患者感觉、情感、认知和社会维度的痛苦体验,在治疗患者原发疾病的同时,改善患者的心理需求和社会功能需求。通过查阅文献,本共识专家组遵循循证医学原则,经过反复讨论和通信修改,对肌肉骨骼系统慢性疼痛管理达成共识,供广大骨科医师在临床工作中参考。     

血液病科2011-2013年临床标本分离病原菌及耐药性分析

目的分析血液病科近3年临床送检标本病原菌分布及耐药情况。方法收集2011年1月—2013年12月血液病科住院患者送检标本分离菌株,使用K-B法或自动化仪器法进行药敏检测,抗菌药物药敏结果判定依照美国临床试验标准化委员会(CLSI)2011年版指南,应用WHONET5.6软件进行数据统计分析。结果 2011—2013年血液病科临床送检标本共分离病原菌462株,其中革兰阳性球菌161株,革兰阴性杆菌279株,真菌22株。葡萄球菌属中耐甲氧西林凝固酶阴性葡萄球菌(MRSCN)及耐甲氧西林金黄色葡萄球菌(MRSA)的检出率为81.37%和62.50%。葡萄球菌属及肠球菌属细菌对利奈唑胺耐药率分别为1.69%及3.57%,葡萄球菌属细菌对替考拉宁耐药率为3.39%,未检出对万古霉素耐药的革兰阳性球菌。肠杆菌科中大肠埃希菌、肺炎克雷伯菌对碳青霉烯类抗生素高度敏感(敏感率为97.56%~98.88%);而非发酵革兰阴性杆菌铜绿假单胞菌及鲍曼不动杆菌对碳青霉烯类抗生素耐药明显(耐药率为38.71%~64.00%)。结论血液病科主要细菌耐药现象较重,应根据血液病科细菌分布的特点及药敏结果,有针对性地合理应用抗菌药物,加强医院感染控制措施,降低细菌耐药率。